Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1994 Oct;38(4):329-34.
doi: 10.1111/j.1365-2125.1994.tb04362.x.

Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers

Affiliations
Clinical Trial

Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers

R J MacFadyen et al. Br J Clin Pharmacol. 1994 Oct.

Abstract

1. Intravenous ACE inhibitor therapy appears to have a role in the treatment of acute heart failure and early after myocardial infarction. Practical experience with intravenous administration with activation of renin is limited. We report responses to perindoprilat (Pt, 0.67 mg) or placebo (P) infused over 4 h in normotensive male volunteers (n = 12, 19-28 years, 53-77 kg) with double-blind, placebo controlled salt depletion (SD) or salt repletion (SR) as a model of the activated renin system. 2. Salt depletion caused no significant fall in serum sodium (P, 139.4 +/- 2.4; Pt, 138.3 +/- 1.9) compared with salt replete preparation (P, 139.9 +/- 1.2; Pt, 139.7 +/- 0.9) but elevation of plasma renin activity 2-3-fold. Pretreatment baseline systolic blood pressure following salt depletion (P, 121 +/- 9.3/71 +/- 7.9; Pt, 121.5 +/- 9.6/69 +/- 8.1) was higher than following salt replete preparation (P, 114 +/- 9.5/61 +/- 7.2; Pt, 116.9 +/- 6.9/67 +/- 7.2). 3. Baseline corrected supine SBP fell significantly and to a similar extent following active treatment regardless of activation of the renin system (SD, -14.6 +/- 9.5/-9.4 +/- 6.4; SR, -12 +/- 14/-10.1 +/- 6.6) compared with placebo (SD, -6.1 +/- 6/-3.7 +/- 5.6; SR, -4.7 +/- 10/-1.3 +/- 6.5). Heart rate was unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

PubMed Disclaimer

References

    1. Circulation. 1970 Aug;42(2):323-34 - PubMed
    1. J Cardiovasc Pharmacol. 1993 Jul;22(1):27-32 - PubMed
    1. Clin Pharmacol Ther. 1975 Aug;18(2):165-9 - PubMed
    1. Clin Sci (Lond). 1979 Oct;57(4):351-7 - PubMed
    1. Kidney Int. 1981 Aug;20(2):240-5 - PubMed

Publication types

MeSH terms